Phase II evaluation of PIV3 cp45 live, attenuated parainfluenza type 3 vaccine in healthy children 6-18 months of age
Version 2 2024-06-19, 10:03Version 2 2024-06-19, 10:03
Version 1 2022-03-31, 12:34Version 1 2022-03-31, 12:34
conference contribution
posted on 2024-06-19, 10:03authored byEL Anderson, RB Belshe, FK Newman, R Karron, P Wright, D Roberton, K Reisinger, F Henderson, J King, R Loh, P Sly, P McIntyre, J Ziegler, H Keyserling, R Schwartz, G Weinberg, B Murphy, J Tatem, F Gohs, T Tsai, J Hackell, W Gruber
Phase II evaluation of PIV3 cp45 live, attenuated parainfluenza type 3 vaccine in healthy children 6-18 months of age